Free Trial
NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Price, News & Analysis

$0.73
-0.03 (-3.97%)
(As of 05/23/2024 ET)
Today's Range
$0.71
$0.76
50-Day Range
$0.69
$0.85
52-Week Range
$0.67
$5.95
Volume
704,611 shs
Average Volume
979,486 shs
Market Capitalization
$29.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Spruce Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
681.0% Upside
$5.67 Price Target
Short Interest
Healthy
0.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.14mentions of Spruce Biosciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($1.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

296th out of 915 stocks

Pharmaceutical Preparations Industry

125th out of 399 stocks

SPRB stock logo

About Spruce Biosciences Stock (NASDAQ:SPRB)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

SPRB Stock Price History

SPRB Stock News Headlines

Spruce Biosciences, Inc. (SPRB)
Spruce Biosciences Inc (SPRB)
Stocks to Watch: Spruce Biosciences, UiPath
See More Headlines
Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
5/23/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SPRB
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$10.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+681.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-47,920,000.00
Net Margins
-461.67%
Pretax Margin
-461.67%

Debt

Sales & Book Value

Annual Sales
$10.09 million
Book Value
$1.62 per share

Miscellaneous

Free Float
37,410,000
Market Cap
$29.86 million
Optionable
Optionable
Beta
2.50
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Michael G. Grey (Age 71)
    Executive Chairman
    Comp: $70k
  • Dr. Javier Szwarcberg M.D. (Age 54)
    M.P.H., CEO & Director
    Comp: $951.85k
  • Mr. Samir M. Gharib CPA (Age 42)
    M.B.A., President & CFO
    Comp: $683.63k
  • Dr. Ralph William Charlton III (Age 54)
    M.D., Chief Medical Officer
    Comp: $647.4k
  • Ms. P. J. Ramtin
    Senior Vice President of Business Operations
  • Ms. Heidi Petersen M.P.H.
    Senior Vice President of Regulatory & Quality

SPRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPRB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRB, but not buy additional shares or sell existing shares.
View SPRB analyst ratings
or view top-rated stocks.

What is Spruce Biosciences' stock price target for 2024?

8 equities research analysts have issued 12-month target prices for Spruce Biosciences' stock. Their SPRB share price targets range from $2.00 to $10.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 681.0% from the stock's current price.
View analysts price targets for SPRB
or view top-rated stocks among Wall Street analysts.

How have SPRB shares performed in 2024?

Spruce Biosciences' stock was trading at $2.93 at the beginning of the year. Since then, SPRB stock has decreased by 75.2% and is now trading at $0.7256.
View the best growth stocks for 2024 here
.

When is Spruce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our SPRB earnings forecast
.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.18. The business earned $2.89 million during the quarter, compared to the consensus estimate of $1.65 million. Spruce Biosciences had a negative net margin of 461.67% and a negative trailing twelve-month return on equity of 57.53%.

When did Spruce Biosciences IPO?

Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

Who are Spruce Biosciences' major shareholders?

Spruce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (3.67%), Acadian Asset Management LLC (0.90%) and AWM Investment Company Inc. (0.49%).
View institutional ownership trends
.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRB) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners